Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 1
2006 1
2007 1
2008 2
2009 6
2010 7
2011 2
2012 3
2013 2
2014 1
2015 6
2016 4
2017 5
2018 8
2019 10
2020 10
2021 14
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Results by year
Filters applied: . Clear all
Page 1
3-Chloro-4-[18F]fluorophenyl-(4-fluoro-4-[[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl]-piperidin-1-yl)methanone (F15599).
Leung K. Leung K. 2012 Jun 20 [updated 2012 Oct 11]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 Jun 20 [updated 2012 Oct 11]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 23077753 Free Books & Documents. Review.
However, none of these antagonists distinguishes between the high- and low-affinity states of the 5-HT(1A) receptors. The high-affinity state of the receptor is coupled to G-proteins, which mediate cell functions by providing intracellular signals. 2-(4-(4
However, none of these antagonists distinguishes between the high- and low-affinity states of the 5-HT(1A) receptors. The high-affini …
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.
Depoortere R, Johnston TH, Fox SH, Brotchie JM, Newman-Tancredi A. Depoortere R, et al. Parkinsonism Relat Disord. 2020 Sep;78:151-157. doi: 10.1016/j.parkreldis.2020.08.009. Epub 2020 Aug 13. Parkinsonism Relat Disord. 2020. PMID: 32846366
METHODS: The effects of NLX-112 (0.03, 0.1 and 0.3 mg/kg PO) on established LID evoked by acute challenge with l-DOPA (27.5 3.8 mg/kg PO) were assessed in MPTP-treated cynomolgus macaques. Amantadine (10 mg/kg PO) was tested as a positive …
METHODS: The effects of NLX-112 (0.03, 0.1 and 0.3 mg/kg PO) on established LID evoked by acute challenge with l …
Serotonin 5-HT1A Receptor Biased Agonists Induce Different Cerebral Metabolic Responses: A [18F]-Fluorodesoxyglucose Positron Emission Tomography Study in Conscious and Anesthetized Rats.
Levigoureux E, Vidal B, Fieux S, Bouillot C, Emery S, Newman-Tancredi A, Zimmer L. Levigoureux E, et al. ACS Chem Neurosci. 2019 Jul 17;10(7):3108-3119. doi: 10.1021/acschemneuro.8b00584. Epub 2019 Jan 7. ACS Chem Neurosci. 2019. PMID: 30576601
Several 5-HT(1A) receptor biased agonists are currently in development, including NLX-101 (aka F15599) and NLX-112 (aka F13640, befiradol), with preclinical data suggesting that they preferentially target different populatio …
Several 5-HT(1A) receptor biased agonists are currently in development, including NLX-101 (aka F15599) and NL
NLX-112, a highly selective 5-HT1A receptor agonist: Effects on body temperature and plasma corticosterone levels in rats.
Newman-Tancredi A, Depoortère R, Carilla-Durand E, Tarayre JP, Kleven M, Koek W, Bardin L, Varney MA. Newman-Tancredi A, et al. Pharmacol Biochem Behav. 2018 Feb;165:56-62. doi: 10.1016/j.pbb.2017.11.002. Epub 2017 Nov 7. Pharmacol Biochem Behav. 2018. PMID: 29126856
NLX-112 (a.k.a. F13640 or befiradol), exhibits nanomolar affinity, exceptional selectivity and high agonist efficacy at 5-hydroxytryptamine 5-HT(1A) receptors. ...The increase in corticosterone induced by NLX-112 (0.63mg/kg
NLX-112 (a.k.a. F13640 or befiradol), exhibits nanomolar affinity, exceptional selectivity and high agonist effi
Pharmacological MRI to investigate the functional selectivity of 5-HT1A receptor biased agonists.
Vidal B, Bolbos R, Redouté J, Langlois JB, Costes N, Newman-Tancredi A, Zimmer L. Vidal B, et al. Neuropharmacology. 2020 Aug 1;172:107867. doi: 10.1016/j.neuropharm.2019.107867. Epub 2019 Nov 26. Neuropharmacology. 2020. PMID: 31783063
The cerebral blood oxygen level dependent (BOLD) signal changes induced by increasing doses of two serotonin 5-HT(1A) receptor biased agonists, NLX-112 and NLX-101, were mapped in anaesthetized rats. ...Importantly, NLX-101 had no …
The cerebral blood oxygen level dependent (BOLD) signal changes induced by increasing doses of two serotonin 5-HT(1A) receptor biased …
NLX-101, a highly selective 5-HT1A receptor biased agonist, mediates antidepressant-like activity in rats via prefrontal cortex 5-HT1A receptors.
Depoortère R, Auclair AL, Newman-Tancredi A. Depoortère R, et al. Behav Brain Res. 2021 Mar 5;401:113082. doi: 10.1016/j.bbr.2020.113082. Epub 2020 Dec 25. Behav Brain Res. 2021. PMID: 33358917
NLX-101 (also known as F15599) exhibits nanomolar affinity, exceptional selectivity and biased agonist activation of serotonin 5-HT(1A) receptors. ...These data suggest that NLX-101 may target specific 5-HT(1A) receptor subpopulati
NLX-101 (also known as F15599) exhibits nanomolar affinity, exceptional selectivity and biased agonist activation of se
NLX-112, a highly selective 5-HT1A receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT1A receptors, respectively.
Newman-Tancredi A, Bardin L, Auclair A, Colpaert F, Depoortère R, Varney MA. Newman-Tancredi A, et al. Brain Res. 2018 Jun 1;1688:1-7. doi: 10.1016/j.brainres.2018.03.016. Epub 2018 Mar 16. Brain Res. 2018. PMID: 29555239
NLX-112 (a.k.a. F13640 or befiradol) possesses marked activity in a variety of animal models of pain and of neuropsychiatric disorders; it exhibits nanomolar affinity, exceptional selectivity and high agonist efficacy at 5-hydroxytryptamine1A (
NLX-112 (a.k.a. F13640 or befiradol) possesses marked activity in a variety of animal models of pain and of neur
Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.
Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C. Meadows SM, et al. Exp Neurol. 2017 Jun;292:168-178. doi: 10.1016/j.expneurol.2017.03.013. Epub 2017 Mar 23. Exp Neurol. 2017. PMID: 28342749
Both compounds significantly reduced LID, without affecting motor performance, however, acute administration of F13714 significantly induced 5-HT syndrome at anti-dyskinetic doses. In experiment 2, we elucidated the role of striatal 5-HT(1A)R in the effects o …
Both compounds significantly reduced LID, without affecting motor performance, however, acute administration of F13714 significantly induced …
NLX-101, a cortical 5-HT1A receptor biased agonist, reverses scopolamine-induced deficit in the delayed non-matching to position model of cognition.
Depoortere RY, Auclair AL, Newman-Tancredi A. Depoortere RY, et al. Brain Res. 2021 Aug 15;1765:147493. doi: 10.1016/j.brainres.2021.147493. Epub 2021 Apr 20. Brain Res. 2021. PMID: 33887253
NLX-101 is a selective, high efficacy, biased agonist at post-synaptic cortical 5-HT(1A) receptors. ...Moreover, NLX-101 (0.04 and 0.16 mg/kg) dose-dependently and significantly opposed scopolamine-induced impairment for 5 and 10 s delays
NLX-101 is a selective, high efficacy, biased agonist at post-synaptic cortical 5-HT(1A) receptors. ...Moreover, NLX
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets.
Fisher R, Hikima A, Morris R, Jackson MJ, Rose S, Varney MA, Depoortere R, Newman-Tancredi A. Fisher R, et al. Neuropharmacology. 2020 May 1;167:107997. doi: 10.1016/j.neuropharm.2020.107997. Epub 2020 Feb 10. Neuropharmacology. 2020. PMID: 32057799 Free PMC article.
Reducing the activity of these neurons diminishes l-DOPA-induced dyskinesia (LID), but there are currently no clinically approved selective, high efficacy 5-HT(1A) receptor agonists. Here we describe the effects of NLX-112, a highly selective and efficacious …
Reducing the activity of these neurons diminishes l-DOPA-induced dyskinesia (LID), but there are currently no clinically approved selective, …
76 results